Ophthalmology· 2019Q1
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
- 922citations
- Q1SCImago
- 2019year
Short summary
Brolucizumab 6 mg demonstrated noninferiority to aflibercept in visual acuity gains for neovascular AMD, with over 50% of patients maintained on a less frequent 12-week dosing schedule.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Ophthalmology
OphthalmologyMedicine